Who owns SARQUAVITAE?

SARQUAVITAE has been 100% owned by DOMUSVI since October 2016.

At what enterprise value was SARQUAVITAE acquired in 2016?

During the acquisition of SARQUAVITAE by DOMUSVI in 2016, the transaction's Enterprise Value is estimated to be in the range of 300M - 700M EUR.

What was the EV/EBITDA of SARQUAVITAE when it was acquired by DOMUSVI?

The estimated EV/EBITDA multiple for SARQUAVITAE is in the range of 10x - 18x.

When was SARQUAVITAE acquired by DOMUSVI?

SARQUAVITAE was acquired by DOMUSVI in 2016.

What was the revenue of SARQUAVITAE at the time of the deal?

The revenue of SARQUAVITAE at the time of the deal is estimated to be in the range of 250M - 500M EUR.

What was the EBITDA of SARQUAVITAE during the acquisition?

SARQUAVITAE's EBITDA is estimated to be in the range of 25M - 50M EUR.

How is the data for the SARQUAVITAE acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the SARQUAVITAE deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.pemagazine.fr/nti1mw-excellente-sante-financiere-pour-domusvi/

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaSARQUAVITAE

10/2016

SARQUAVITAE acquired by DOMUSVI

SPAIN Health Providers / Healthcare Facilities / Nursing Homes EV 300M - 700M EUR

Context

DomusVi has successfully acquired its Spanish competitor SARquavitae, previously held by a consortium of investment funds including Palamon Capital Partners and G Square Capital. This transformative build-up operation allows the group to become the number one player in the Spanish elderly care market. The strategic rationale centers on geographic diversification, as the target’s strong footprint in Catalonia and Madrid perfectly complements the acquirer’s existing position in Galicia. The integration adds 88 facilities and 11,000 beds to the group’s portfolio, bringing total pro forma revenues to approximately €1.2 billion. This acquisition marks a significant milestone in the group’s international expansion strategy, following the previous year’s integration of another Spanish operator, thereby solidifying its leadership position in Southern Europe.

SARQUAVITAE, which reported an EBITDA margin of in 2016, is valued in this transaction at an EV/EBITDA multiple of , representing a level the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

SARquavitae is a leading Spanish provider of elderly care services, operating an extensive network of 88 facilities with a total capacity of 11,000 beds. The entity maintains a particularly strong strategic presence in key regions including Catalonia and Madrid, complementing its historical operations. Its business model focuses on residential care and specialized medical services for the dependent elderly population. The company provides high-quality clinical and hospitality services, positioning itself as a primary competitor in the Iberian long-term care market. By integrating advanced healthcare management protocols, the group ensures a stable value proposition for both private residents and public regional healthcare systems. The organization has demonstrated consistent growth and operational stability, making it a pivotal asset for consolidation in the European healthcare infrastructure landscape.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2016

2015

Similar deals in Health Providers

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
01/2017	PARTNERS GROUP / PSP INVESTMENTS	CERBA HEALTHCARE	FRANCE	Labs (Biology)
01/2017	MARS	VCA	UNITED STATES	Vet Clinics
05/2016	VCA	Companion Animal Practices	UNITED STATES	Vet Clinics
03/2016	F2I SGR / CIR - COMPAGNIE INDUSTRIALI RIUNITE	KOS GROUP	ITALY	Nursing Homes
02/2016	OMERS	Forefront Dermatology	UNITED STATES	Outpatient Care
08/2015	CINVEN	SYNLAB	GERMANY	Labs (Biology)
07/2015	ANTIN INFRASTRUCTURE	AMEDES	GERMANY	Labs (Biology)
05/2015	CINVEN	LABCO	FRANCE	Labs (Biology)
01/2015	CERBA HEALTHCARE	NOVESCIA	FRANCE	Labs (Biology)
10/2014	WATERLAND	MEDIAN KLINIKEN	GERMANY	Clinics / Hospitals

REFERENCES

Valuation range: EV 300M - 700M EUR

Revenue range: 250M - 500M EUR

EBITDA range: 25M - 50M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of SARQUAVITAE by DOMUSVI are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.